Tat-BMPs-PAMAM conjugates enhance therapeutic effect of small interference RNA on U251 glioma cells in vitro and in vivo

Human Gene Therapy

Volumn 21, Issue 4, 2010, Pages 417-426

  Han, Lei ^a,b   Zhang, Anling ^b   Wang, Hanjie ^a   Pu, Peiyu ^b   Jiang, Xinguo ^c   Kang, Chunsheng ^b   Chang, Jin ^a  

^a TIANJIN UNIVERSITY   (China)

^b TIANJIN MEDICAL UNIVERSITY   (China)

^c FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; CYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR; GELATINASE A; GELATINASE B; LIPOFECTAMINE; NANOPARTICLE; PHOSPHATE BUFFERED SALINE; POLYAMIDOAMINE; PROTEIN BCL 2; PROTEIN KINASE B; SMALL INTERFERING RNA; TRANSACTIVATOR PROTEIN; TRANSACTIVATOR PROTEIN BACTERIAL MAGNETIC NANOPARTICLE POLYAMIDOAMINE; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL INVASION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; ELECTRICITY; GENE DELIVERY SYSTEM; GENE EXPRESSION; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MITOSIS INHIBITION; MOUSE; NONHUMAN; OPEN READING FRAME; PLASMID; THERAPY EFFECT; TUMOR GROWTH;

ANIMALS; BRAIN NEOPLASMS; DENDRIMERS; DRUG DELIVERY SYSTEMS; GENE THERAPY; GLIOMA; HUMANS; LIPIDS; METAL NANOPARTICLES; MICE; MICE, NUDE; PEPTIDE FRAGMENTS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA INTERFERENCE; RNA, SMALL INTERFERING; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

BACTERIA (MICROORGANISMS); MUS MUSCULUS;

EID: 77950948806     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2009.087     Document Type: Article

References (26)

1. Blakemore, R.P. (1975). Magnetotactic bacteria. Science 190, 377-379.
2. Christine, D., Ijeoma, F.U., and Andreas, G.S. (2005). Dendrimer in gene delivery. Adv. Drug Deliv. Rev. 57, 2177-2202.
3. Dailey, L.A., Kleemann, E., Merdan, T., Petersen, H., Schmehl, T., Gessler, T., Hanze, J., Seeger, W., and Kissel, T. (2004). Modified polyethylenimines as non viral gene delivery systems for aerosol therapy: Effects of nebulization on cellular uptake and transfection efficiency. J. Control. Release 100, 425-436.
4. Gou, M., Qian, Z., Wang, H., Tang, Y., Huang, M., Kan, B., Wen, Y., Dai, M., Li, X., Gong, C, and Tu, M. (2008). Preparation and characterization of magnetic poly(c-caprolactone)-poly(ethylene glycol)-poly(c-caprolactone) microspheres. J. Mater. Sci. Mater. Med. 19, 1033-1041.
5. Han, L., Li, S.Y., Yang, Y., Zhao, F.M., Huang, J., and Chang, J. (2007). Comparison of magnetite nanocrystal formed by bio-mineralization and chemosynthesis. J. Magn. Magn. Mater. 313, 236-242.
6. Han, L., Zhang, A.L., Xu, P., Yue, X., Yang, Y., Wang, G.X., Jia, Z.F., Pu, P.Y., and Kang, C.S. (2009). Combination gene therapy with PTEN and EGFR siRNA suppresses U251 malignant glioma cell growth in vitro and in vivo. Med. Oncol, (in proof, DOI: 10.1007/sl2032-009-9295-8).
7. Huang, M., Gou, M., Qian, Z., Dai, M., Li, X., Cao, M., Wang, K., Zhao, J., Yang, J., Lu, Y., Tu, M., and Wei, Y. (2008). One-step preparation of poly(£-caprolactone)-poly(ethylene glycol)-poly(c-caprolactone) nanoparticles for plasmid DNA delivery. J. Biomed. Mater. Res. A 86, 979-986.
8. Jia, W., Liu, J., Zhang, Y., Wang, J., Wang, J., Sun, C, Pan, Y., Yu, C, Li, G., Zhang, H., Gou, M., Tu, M., and Qian, Z. (2007). Preparation, characterization, and optimization of pancreas-targeted 5-Fu loaded magnetic bovine serum albumin microspheres. J. Drug Target. 15, 140-145. (Pubitemid 46957700)
9. Johansson, B.B. (1990). The physiology of the blood-brain barrier. Adv. Exp. Med. Biol. 274, 25-39.
10. Kang, C, Pu, P., Li, H., Zhang, Z., Qiu, M., Huang, Q., and Wang, G. (2005). An in vitro study on the suppressive effect of glioma cell growth induced by plasmid-based small interference RNA (siRNA) targeting human epidermal growth factor receptor. J. Neurooncol. 74, 267-273.
11. Kang, C, Zhang, Z., Jia. Z., Wang, G., Qiu, M., Zhou, H., Yu, S., Chang, J., Jiang, H., and Pu, P. (2006). Suppression of EGFR expression by antisense or small interference RNA inhibits U251 glioma cell growth in vitro and in vivo. Cancer Gene Ther. 13, 530-538.
12. Lee, J., Tung, C.H., Anna, M., and Ralph, W. (1999). High-efficiency intracellular magnetic labeling with novel super-paramagnetic-Tat peptide conjugates. Bioconjug. Chem. 10, 186-191.
13. Lewin, M., Carlesso, N., Tung, C.H., Tang, X.W., Cory, D., Scadden, D.T., and Weissleder, R. (2000). Tat peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells. Nat. Biotechnol. 18, 410-414
14. Lindgren, M., Hallbrink, M., Prochiantz, A., and Langel, U. (2000). Cell-penetrating peptides. Trends Pharmacol. Sci. 21, 99-103.
15. Liu, L.H., Guo, K., Lu, J., Venkatraman, S.S., Luo, D., Ng, K.C., Ling, E.A., Moochhala, S., and Yang, Y.Y. (2008). Biologically active core/shell nanoparticles self-assembled from cholesterol-terminated PEG-TAT for drug delivery across the blood-brain barrier. Biomaterials 29, 1509-1517.
16. Mendelsohn, J., and Baselga, J. (2000). The EGF receptor family as targets for cancer therapy. Oncogene 19, 6550-6665.
17. Pan, B.F., Gao, F., and Gu, H.C. (2005). Dendrimer modified magnetite nanoparticles for protein immobilization. J. Colloid Interface Sci. 284, 1-6. (Pubitemid 40332441)
18. Pan, B.F., Cui, D.X., Sheng, Y., Ozkan, C, Gao, F., He, R., Li, Q., Xu, P., and Huang, T. (2007). Dendrimer-modified magnetic nanoparticles enhance efficiency of gene delivery system. Cancer Res. 67, 8156-8163.
19. Pu, P.P., Kang, C.S., Zhang, Z.Y., Liu, X.Z., and Jiang, H. (2006). Downregulation of PIK3CB by siRNA suppresses malignant glioma cell growth in vitro and in vivo. Tech. Cancer Res. Treat. 5, 271-280. (Pubitemid 43946260)
20. Rudolf, H., Robert, H., Matthias, Z., Dirk, S., Udo, H., Ingrid, H., and Werner, A.K. (2005). Magnetic properties of bacterial magnetosomes as potential diagnostic and therapeutic tools. J. Magn. Magn. Mater. 293, 80-86.
21. Stewart, L.A. (2002). Chemotherapy in adult high-grade glioma: A systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 359, 1011-1018.
22. Tueng, S., Ralph, W., Mikhail, P., Alexei, B., and Thomas, J.B. (1993). Monocrystalline iron oxide nanocompounds (MION): Physicochemical properties. Magn. Reson. Med. 29, 599-604.
23. Watanabe, K., Tachibana, O., Sato, K., Yonekawa, Y., Kleihues, P., and Ohgaki, H. (1996). Over-expression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol. 6,217-223.
24. Wells, A. (1999). EGF receptor. Int. J. Biochem. Cell. Biol. 31, 637-643.
25. Zhao, J., Gou, M., Dai, M., Li, X., Cao, M., Huang, M., Wen, Y., Kan, B., Qian, Z., and Wei, Y. (2009). Preparation, characterization, and in vitro cytotoxicity study of cationic PCL-Pluro-nic-PCL (PCFC) nanoparticles for gene delivery. J. Biomed. Mater. Res. A 90, 506-513.
26. Zhao, M., Kircher, M., Josephson, L., and Ralph, W. (2002). Differential conjugation of Tat peptide to superparamagnetic nanoparticles and its effect on cellular uptake. Bioconjug. Chem. 13, 840-844.